Postprogression prolongation of survival in EGFR-mutated lung cancer: Reconciling the ASPIRATION and IMPRESS trials

David R. Gandara; Mary Redman; Fred R. Hirsch

doi:10.1001/jamaoncol.2015.4920

Postprogression prolongation of survival in EGFR-mutated lung cancer: Reconciling the ASPIRATION and IMPRESS trials

David R. Gandara, Mary Redman, Fred R. Hirsch

Research output: Contribution to journal › Editorial

4 Scopus citations

Original language	English
Pages (from-to)	300-301
Number of pages	2
Journal	JAMA Oncology
Volume	2
Issue number	3
DOIs	https://doi.org/10.1001/jamaoncol.2015.4920
State	Published - Mar 2016
Externally published	Yes

Access to Document

10.1001/jamaoncol.2015.4920

Cite this

@article{472ca3b1ca434b6dbec39a7c0f9b16f1,

title = "Postprogression prolongation of survival in EGFR-mutated lung cancer: Reconciling the ASPIRATION and IMPRESS trials",

author = "Gandara, {David R.} and Mary Redman and Hirsch, {Fred R.}",

note = "Funding Information: Dr Gandara, has received grants from Genentech and has been a consultant for AstraZeneca, Genentech, and Boehringer-Ingelheim. Dr Hirsch, has received compensation for being a member of the advisory board of Genentech/Roche, AstraZeneca, BMS, Lilly, Pfizer, Clovis, and Boehringer-Ingelheim, and has received research funding (through University of Colorado) from Lilly, Celgene, Genentech, Bayer, Merck, Amgen, and BMS. No other disclosures are reported.",

year = "2016",

month = mar,

doi = "10.1001/jamaoncol.2015.4920",

language = "English",

volume = "2",

pages = "300--301",

journal = "JAMA Oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "3",

}

TY - JOUR

T1 - Postprogression prolongation of survival in EGFR-mutated lung cancer

T2 - Reconciling the ASPIRATION and IMPRESS trials

AU - Gandara, David R.

AU - Redman, Mary

AU - Hirsch, Fred R.

N1 - Funding Information: Dr Gandara, has received grants from Genentech and has been a consultant for AstraZeneca, Genentech, and Boehringer-Ingelheim. Dr Hirsch, has received compensation for being a member of the advisory board of Genentech/Roche, AstraZeneca, BMS, Lilly, Pfizer, Clovis, and Boehringer-Ingelheim, and has received research funding (through University of Colorado) from Lilly, Celgene, Genentech, Bayer, Merck, Amgen, and BMS. No other disclosures are reported.

PY - 2016/3

Y1 - 2016/3

UR - http://www.scopus.com/inward/record.url?scp=84979567697&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2015.4920

DO - 10.1001/jamaoncol.2015.4920

M3 - Editorial

C2 - 26720042

AN - SCOPUS:84979567697

SN - 2374-2437

VL - 2

SP - 300

EP - 301

JO - JAMA Oncology

JF - JAMA Oncology

IS - 3

ER -